Illumina will grant Roche rights to develop and distribute IVD tests on its Dx sequencing instruments, while Roche will help expand the CDx claims for Illumina's solid tumor panel.
ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.
Under the agreement, Prometheus will receive an upfront payment of an undisclosed amount and could receive up to $420 million in milestone payments.
The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.
The firm said that the funding may be used to support further development of its portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes.
Abionic will conduct all premarket process requirements for the test, while Genentech will fund the clinical and regulatory costs associated with the test.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.
Chembio said it will receive funding subject to satisfying milestones to develop a test that leverages its immunoassay platform and hand-held optical analyzer.
Chembio said it will receive funding to develop a test that combines its Dual Path Platform (DPP) technology with a Perseus concussion biomarker.